Global Cereblon E3 Ligase Modulators (CELMoDs) Clinical Trials & Market Opportunity Insight 2026
Highlights & Findings:
The global Cereblon E3 Ligase Modulators (CELMoDs) market has evolved from the realm of scientific discovery to become a highly advanced clinical-stage segment within targeted protein degradation and immuno-oncology. CELMoDs are the next generation of immunomodulatory drugs that aim to improve the Cereblon mediated protein degradation process with higher selectivity and potency. Through the process of degradation of transcription factors such as IKZF1 and IKZF3, CELMoD drugs restore immune surveillance and generate anti-tumor activity, especially in hematologic cancers including multiple myeloma. The current generation of CELMoDs shows better cereblon binding properties and increased immune activation compared to the previous generation of IMiDs.
As of June 2026, there is no CELMoD that has gained full regulatory approval, but the pipeline has now reached a turning point in terms of progress in clinical trials. There are some agents such as iberdomide, mezigdomide, and golcadomide that have progressed to pivotal stages, with attention now increasingly shifting towards combination treatments using monoclonal antibodies and corticosteroids. Iberdomide has been especially important in terms of the clinical development of this class, with regulatory filings for relapsed or refractory multiple myeloma having been made possible due to deep responses observed in the Phase 3 study of the candidate, including negative results for measurable residual disease. This move from preclinical biology to near-commercialization makes CELMoDs one of the most interesting and exciting new classes of drugs in the field of oncology.
The purpose of this report is to offer a systematic analysis of the landscape of cereblon modulation technology for investors, pharmaceutical companies, and other parties with an interest in the sector. The report offers an assessment of scientific advances, clinical development trends, competitive dynamics, and commercial strategy trends in the field of cereblon modulation. With rapid advancements in the field, the report not only highlights the present clinical situation but also provides an insight into the future direction of these therapies.
Clinical Trials Insight Included In Report
CELMoD therapeutic research is largely based on current clinical investigations in hematological cancers, especially relapsed and refractory multiple myeloma where there is still significant unmet medical need. Current clinical investigations for CELMoDs include their use in combination with existing backbone therapies such as CD38 antibodies, proteasome inhibitors, and steroids. Combination therapies are at the forefront of current research activities since they not only maximize immune activation but also tackle mechanisms that cause resistance to existing drugs. Clinical trials show a consistent trend whereby CELMoDs are more effective and lead to prolonged responses than previous immunomodulatory drugs.
However, apart from being tested in multiple myeloma, CELMoDs have also been tested in other hematologic tumors such as lymphomas and certain solid tumors like renal cell carcinomas. Although hematologic cancers remain the primary focus of the CELMoD pipeline, these exploratory clinical investigations indicate the belief that the cereblon modulating drugs can be used to treat other forms of cancer too. The increased number of clinical trial types, such as adaptive studies and biomarker-selected cohorts, indicates the shift towards precision oncology research.
Major Companies Driving CELMoD Research & Development
The current leading organizations in the CELMoD space include a select few large pharmaceutical companies that possess immuno-oncology pipelines. Bristol Myers Squibb is one of the leaders of clinical developments in the CELMoD space with a pipeline that consists of iberdomide, mezigdomide, golcadomide, and several other compounds that are in the early stages of development. Iberdomide, in particular, is undergoing evaluation in numerous lines of treatment, which suggests that the organization's strategy is to integrate the modulators of cereblon into various existing oncology treatments. The regulatory acceptance of iberdomide has reinforced the firm's position within the global CELMoD market.
In addition to large pharmaceutical companies, biotechnology firms have started making significant contributions to the field. Organizations such as C4 Therapeutics are working on developing next-generation cereblon modulators and molecular glue degraders for expanding the range of protein targets. In addition, strategic collaborations between different organizations play a crucial role in the development of the CELMoD drugs. In particular, the integration of computational biology and cereblon research through collaboration with AI-based discovery platforms and drug development experts is a key strategy for accelerating the process.
Future Outlook For CELMoD Targeting Therapies
The future directions for CELMoD research will include exploration beyond the use of transcription factors as the targets for cellular proteolysis to a greater number of disease-causing proteins. In addition, advances in cereblon modification and molecular glue technologies allow researchers to explore other degradation routes, thus extending the range of potential applications for CELMoDs. Artificial intelligence and omics technologies are gaining in importance in such research due to their ability to find novel targets and streamline drug discovery.
The use of combination therapies will also likely continue to play an important role in the development of CELMoDs, especially in the early lines of cancer therapy. With more clinical data being generated, CELMoDs may soon find their way into the first-line treatment along with other immune-oncology drugs and targeted therapies. Patient stratification based on biomarkers is another promising avenue of research, as it can help improve treatment efficacy through precision medicine approaches.
- Research Methodology
- First Cereblon E3 Ligase Modulator Drug Expected By 2030
- Market Relevance Of Cereblon E3 Ligase Modulators Drugs
- Insight On Cereblon E3 Ligase Modulator Drugs In Clinical Trials: > 20 Drugs
- Cereblon E3 Ligase Modulators Clinical Trials Insight By Company, Country, Indication & Phase
- Key Drugs Clinical Study Initiation & Completion Year
- Current Development Scenario & Future Opportunity Outlook
- Competitive Landscape
The global Cereblon E3 Ligase Modulators (CELMoDs) market has evolved from the realm of scientific discovery to become a highly advanced clinical-stage segment within targeted protein degradation and immuno-oncology. CELMoDs are the next generation of immunomodulatory drugs that aim to improve the Cereblon mediated protein degradation process with higher selectivity and potency. Through the process of degradation of transcription factors such as IKZF1 and IKZF3, CELMoD drugs restore immune surveillance and generate anti-tumor activity, especially in hematologic cancers including multiple myeloma. The current generation of CELMoDs shows better cereblon binding properties and increased immune activation compared to the previous generation of IMiDs.
As of June 2026, there is no CELMoD that has gained full regulatory approval, but the pipeline has now reached a turning point in terms of progress in clinical trials. There are some agents such as iberdomide, mezigdomide, and golcadomide that have progressed to pivotal stages, with attention now increasingly shifting towards combination treatments using monoclonal antibodies and corticosteroids. Iberdomide has been especially important in terms of the clinical development of this class, with regulatory filings for relapsed or refractory multiple myeloma having been made possible due to deep responses observed in the Phase 3 study of the candidate, including negative results for measurable residual disease. This move from preclinical biology to near-commercialization makes CELMoDs one of the most interesting and exciting new classes of drugs in the field of oncology.
The purpose of this report is to offer a systematic analysis of the landscape of cereblon modulation technology for investors, pharmaceutical companies, and other parties with an interest in the sector. The report offers an assessment of scientific advances, clinical development trends, competitive dynamics, and commercial strategy trends in the field of cereblon modulation. With rapid advancements in the field, the report not only highlights the present clinical situation but also provides an insight into the future direction of these therapies.
Clinical Trials Insight Included In Report
CELMoD therapeutic research is largely based on current clinical investigations in hematological cancers, especially relapsed and refractory multiple myeloma where there is still significant unmet medical need. Current clinical investigations for CELMoDs include their use in combination with existing backbone therapies such as CD38 antibodies, proteasome inhibitors, and steroids. Combination therapies are at the forefront of current research activities since they not only maximize immune activation but also tackle mechanisms that cause resistance to existing drugs. Clinical trials show a consistent trend whereby CELMoDs are more effective and lead to prolonged responses than previous immunomodulatory drugs.
However, apart from being tested in multiple myeloma, CELMoDs have also been tested in other hematologic tumors such as lymphomas and certain solid tumors like renal cell carcinomas. Although hematologic cancers remain the primary focus of the CELMoD pipeline, these exploratory clinical investigations indicate the belief that the cereblon modulating drugs can be used to treat other forms of cancer too. The increased number of clinical trial types, such as adaptive studies and biomarker-selected cohorts, indicates the shift towards precision oncology research.
Major Companies Driving CELMoD Research & Development
The current leading organizations in the CELMoD space include a select few large pharmaceutical companies that possess immuno-oncology pipelines. Bristol Myers Squibb is one of the leaders of clinical developments in the CELMoD space with a pipeline that consists of iberdomide, mezigdomide, golcadomide, and several other compounds that are in the early stages of development. Iberdomide, in particular, is undergoing evaluation in numerous lines of treatment, which suggests that the organization's strategy is to integrate the modulators of cereblon into various existing oncology treatments. The regulatory acceptance of iberdomide has reinforced the firm's position within the global CELMoD market.
In addition to large pharmaceutical companies, biotechnology firms have started making significant contributions to the field. Organizations such as C4 Therapeutics are working on developing next-generation cereblon modulators and molecular glue degraders for expanding the range of protein targets. In addition, strategic collaborations between different organizations play a crucial role in the development of the CELMoD drugs. In particular, the integration of computational biology and cereblon research through collaboration with AI-based discovery platforms and drug development experts is a key strategy for accelerating the process.
Future Outlook For CELMoD Targeting Therapies
The future directions for CELMoD research will include exploration beyond the use of transcription factors as the targets for cellular proteolysis to a greater number of disease-causing proteins. In addition, advances in cereblon modification and molecular glue technologies allow researchers to explore other degradation routes, thus extending the range of potential applications for CELMoDs. Artificial intelligence and omics technologies are gaining in importance in such research due to their ability to find novel targets and streamline drug discovery.
The use of combination therapies will also likely continue to play an important role in the development of CELMoDs, especially in the early lines of cancer therapy. With more clinical data being generated, CELMoDs may soon find their way into the first-line treatment along with other immune-oncology drugs and targeted therapies. Patient stratification based on biomarkers is another promising avenue of research, as it can help improve treatment efficacy through precision medicine approaches.
1. RESEARCH METHODOLOGY
2. INTRODUCTION TO CEREBLON E3 LIGASE MODULATORS (CELMODS)
2.1 Overview Of Targeted Protein Degradation (TPD) Landscape
2.2 Evolution Of CRBN Based Therapeutics (IMiDs To CELMoDs)
2.3 Market Relevance & Unmet Needs In Oncology & Beyond
3. BASICS OF CEREBLON E3 LIGASE MODULATORS (CELMODS) BIOLOGY
3.1 Definition & Core Concept Of CELMoDs
3.2 CRBN Complex & Protein Degradation Pathway (Ubiquitin-Proteasome System)
3.3 Positioning Within TPD: IMiDs vs CELMoDs vs PROTACs
4. MECHANISM OF ACTION & DRUG CLASS CHARACTERISTICS
4.1 CRBN Mediated Molecular Glue Mechanism
4.2 Target Protein Degradation & Downstream Effects
4.3 Therapeutic Outcomes & Resistance Mechanisms
5. GLOBAL CEREBLON E3 LIGASE MODULATORS (CELMODS) MARKET OVERVIEW
5.1 Current Clinical Development & Market Scenario
5.2 Future Market Outlook
6. CEREBLON E3 LIGASE MODULATORS (CELMODS) – CLINICAL DEVELOPMENT TRENDS BY INDICATION
6.1 Cancer
6.1.1 Hematological Malignancies
6.1.2 Solid Cancers
6.2 Hematological Disorders
6.3 Autoimmune & Inflammatory Diseases
6.4 Microbial Infections
7. CEREBLON E3 LIGASE MODULATORS (CELMODS) DEVELOPMENT ANALYSIS BY REGION
7.1 US
7.2 Europe
7.3 China
8. GLOBAL CEREBLON E3 LIGASE MODULATORS (CELMODS) CLINICAL TRIALS OVERVIEW
8.1 By Phase
8.2 By Country
8.3 By Company
8.4 By Indication
9. GLOBAL CEREBLON E3 LIGASE MODULATORS (CELMODS) CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
9.1 Preclinical
9.2 Phase I
9.3 Phase I/II
9.4 Phase II
9.5 Phase III
9.6 Preregistration
10. GLOBAL CEREBLON E3 LIGASE MODULATORS (CELMODS) MARKET DYNAMICS
10.1 Market Drivers & Opportunities
10.2 Challenges & Strategic Solutions
11. COMPETITIVE LANDSCAPE
11.1 BioTheryX
11.2 Bristol Myers Squibb
11.3 C4 Therapeutics
11.4 Chia Tai Tianqing Pharmaceutical Group
11.5 Decoy Therapeutics
11.6 Degron Therapeutics
11.7 Evotec
11.8 GluBio Therapeutics
11.9 Gluetacs Therapeutics
11.10 Kangpu Biopharmaceuticals
2. INTRODUCTION TO CEREBLON E3 LIGASE MODULATORS (CELMODS)
2.1 Overview Of Targeted Protein Degradation (TPD) Landscape
2.2 Evolution Of CRBN Based Therapeutics (IMiDs To CELMoDs)
2.3 Market Relevance & Unmet Needs In Oncology & Beyond
3. BASICS OF CEREBLON E3 LIGASE MODULATORS (CELMODS) BIOLOGY
3.1 Definition & Core Concept Of CELMoDs
3.2 CRBN Complex & Protein Degradation Pathway (Ubiquitin-Proteasome System)
3.3 Positioning Within TPD: IMiDs vs CELMoDs vs PROTACs
4. MECHANISM OF ACTION & DRUG CLASS CHARACTERISTICS
4.1 CRBN Mediated Molecular Glue Mechanism
4.2 Target Protein Degradation & Downstream Effects
4.3 Therapeutic Outcomes & Resistance Mechanisms
5. GLOBAL CEREBLON E3 LIGASE MODULATORS (CELMODS) MARKET OVERVIEW
5.1 Current Clinical Development & Market Scenario
5.2 Future Market Outlook
6. CEREBLON E3 LIGASE MODULATORS (CELMODS) – CLINICAL DEVELOPMENT TRENDS BY INDICATION
6.1 Cancer
6.1.1 Hematological Malignancies
6.1.2 Solid Cancers
6.2 Hematological Disorders
6.3 Autoimmune & Inflammatory Diseases
6.4 Microbial Infections
7. CEREBLON E3 LIGASE MODULATORS (CELMODS) DEVELOPMENT ANALYSIS BY REGION
7.1 US
7.2 Europe
7.3 China
8. GLOBAL CEREBLON E3 LIGASE MODULATORS (CELMODS) CLINICAL TRIALS OVERVIEW
8.1 By Phase
8.2 By Country
8.3 By Company
8.4 By Indication
9. GLOBAL CEREBLON E3 LIGASE MODULATORS (CELMODS) CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
9.1 Preclinical
9.2 Phase I
9.3 Phase I/II
9.4 Phase II
9.5 Phase III
9.6 Preregistration
10. GLOBAL CEREBLON E3 LIGASE MODULATORS (CELMODS) MARKET DYNAMICS
10.1 Market Drivers & Opportunities
10.2 Challenges & Strategic Solutions
11. COMPETITIVE LANDSCAPE
11.1 BioTheryX
11.2 Bristol Myers Squibb
11.3 C4 Therapeutics
11.4 Chia Tai Tianqing Pharmaceutical Group
11.5 Decoy Therapeutics
11.6 Degron Therapeutics
11.7 Evotec
11.8 GluBio Therapeutics
11.9 Gluetacs Therapeutics
11.10 Kangpu Biopharmaceuticals
LIST OF TABLES
Table 2-1: TPD vs. Conventional Inhibitors
Table 2-2: Clinically Relevant E3 Ligases In TPD
Table 2-3: IMiDs vs CELMoDs Comparison
Table 2-4: Competitive Positioning Of CELMoDs In Oncology
Table 3-1: IMiDs vs CELMoDs vs PROTACs
Table 2-1: TPD vs. Conventional Inhibitors
Table 2-2: Clinically Relevant E3 Ligases In TPD
Table 2-3: IMiDs vs CELMoDs Comparison
Table 2-4: Competitive Positioning Of CELMoDs In Oncology
Table 3-1: IMiDs vs CELMoDs vs PROTACs
LIST OF FIGURES
Figure 2-1: Ubiquitin Proteasome System Overview
Figure 2-2: Evolution Of Cancer Therapy: From Chemotherapy To Targeted Protein Degradation
Figure 2-3: Key Advantages Of TPD
Figure 2-4: Evolution Of CRBN - Based Therapeutics Timeline
Figure 2-5: Mechanism Of IMiD/CELMoD-Induced Protein Degradation
Figure 2-6: CRBN Signaling In Multiple Myeloma
Figure 2-7: Targeted Protein Degradation Expands The Druggable Proteome
Figure 2-8: Elderly & Comorbid Patient Care Positioning
Figure 3-1: CELMoD Evolution: From IMiDs To Next Generation CELMoDs
Figure 3-2: Event-Driven vs. Occupancy-Driven Pharmacology
Figure 3-3: Multi-Layer Anti-Tumor Mechanism Of CELMODs
Figure 3-4: Canonical Ubiquitination Cascade
Figure 3-5: Structure Of CRL4CRBN Complex
Figure 3-6: UPS Crosstalk & Therapeutic Exploitation
Figure 3-7: Advantages Of CELMoDs Over Earlier Imids
Figure 3-8: Why CELMoDs Are Considered Next-Generation Molecular Glues
Figure 4-1: Molecular Glue Mechanism Of CELMoDa
Figure 4-2: Conformational Dynamics Of CRBN
Figure 4-3: Immediate vs Delayed Biological Effects Of CELMoDs
Figure 4-4: Mechanisms Of Resistance To CELMoDs
Figure 4-5: Response vs. Resistance
Figure 5-1: Global CELMoDs Market - Future Opportunities
Figure 6-1: EXCALIBER-RRMM Phase 3 (NCT04975997) Study – Initiation & Completion Year
Figure 6-2: EXCALIBER-Maintenance Phase 3 (NCT05827016) Study – Initiation & Completion Year
Figure 6-3: MagnetisMM-30 Phase 1 (NCT06215118) Study – Initiation & Completion Year
Figure 6-4: SUCCESSOR-2 Phase 3 (NCT05552976) Study – Initiation & Completion Year
Figure 6-5: SUCCESSOR-1 Phase 3 (NCT05519085) Study – Initiation & Completion Year
Figure 6-6: CC-99282-NHL-001 Phase 1/2 (NCT03930953) Study – Initiation & Completion Year
Figure 6-7: 25-229 Phase 1/2 (NCT07356154) Study – Initiation & Completion Year
Figure 6-8: CA236-0001 Phase 1/2 (NCT06697197) Study – Initiation & Completion Year
Figure 6-9: CA230-1019 Phase 1/2 (NCT06481306) Study – Initiation & Completion Year
Figure 6-10: Autoimmune & Inflammatory Diseases - Immune & Inflammatory Outcomes Of CELMoDs
Figure 6-11: CC-90009 (Eragidomide) Antiviral Mechanism
Figure 8-1: Global – Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Phase, 2026
Figure 8-2: Global – Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Country, 2026
Figure 8-3: Global – Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Company, 2026
Figure 8-4: Global – Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Indication, 2026
Figure 10-1: Global CELMoDs Market - Drivers & Opportunities
Figure 2-1: Ubiquitin Proteasome System Overview
Figure 2-2: Evolution Of Cancer Therapy: From Chemotherapy To Targeted Protein Degradation
Figure 2-3: Key Advantages Of TPD
Figure 2-4: Evolution Of CRBN - Based Therapeutics Timeline
Figure 2-5: Mechanism Of IMiD/CELMoD-Induced Protein Degradation
Figure 2-6: CRBN Signaling In Multiple Myeloma
Figure 2-7: Targeted Protein Degradation Expands The Druggable Proteome
Figure 2-8: Elderly & Comorbid Patient Care Positioning
Figure 3-1: CELMoD Evolution: From IMiDs To Next Generation CELMoDs
Figure 3-2: Event-Driven vs. Occupancy-Driven Pharmacology
Figure 3-3: Multi-Layer Anti-Tumor Mechanism Of CELMODs
Figure 3-4: Canonical Ubiquitination Cascade
Figure 3-5: Structure Of CRL4CRBN Complex
Figure 3-6: UPS Crosstalk & Therapeutic Exploitation
Figure 3-7: Advantages Of CELMoDs Over Earlier Imids
Figure 3-8: Why CELMoDs Are Considered Next-Generation Molecular Glues
Figure 4-1: Molecular Glue Mechanism Of CELMoDa
Figure 4-2: Conformational Dynamics Of CRBN
Figure 4-3: Immediate vs Delayed Biological Effects Of CELMoDs
Figure 4-4: Mechanisms Of Resistance To CELMoDs
Figure 4-5: Response vs. Resistance
Figure 5-1: Global CELMoDs Market - Future Opportunities
Figure 6-1: EXCALIBER-RRMM Phase 3 (NCT04975997) Study – Initiation & Completion Year
Figure 6-2: EXCALIBER-Maintenance Phase 3 (NCT05827016) Study – Initiation & Completion Year
Figure 6-3: MagnetisMM-30 Phase 1 (NCT06215118) Study – Initiation & Completion Year
Figure 6-4: SUCCESSOR-2 Phase 3 (NCT05552976) Study – Initiation & Completion Year
Figure 6-5: SUCCESSOR-1 Phase 3 (NCT05519085) Study – Initiation & Completion Year
Figure 6-6: CC-99282-NHL-001 Phase 1/2 (NCT03930953) Study – Initiation & Completion Year
Figure 6-7: 25-229 Phase 1/2 (NCT07356154) Study – Initiation & Completion Year
Figure 6-8: CA236-0001 Phase 1/2 (NCT06697197) Study – Initiation & Completion Year
Figure 6-9: CA230-1019 Phase 1/2 (NCT06481306) Study – Initiation & Completion Year
Figure 6-10: Autoimmune & Inflammatory Diseases - Immune & Inflammatory Outcomes Of CELMoDs
Figure 6-11: CC-90009 (Eragidomide) Antiviral Mechanism
Figure 8-1: Global – Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Phase, 2026
Figure 8-2: Global – Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Country, 2026
Figure 8-3: Global – Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Company, 2026
Figure 8-4: Global – Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Indication, 2026
Figure 10-1: Global CELMoDs Market - Drivers & Opportunities
